Amylx Pharmaceuticals Inc vs Shopify Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.93 (market cap $2.64B), while Shopify Inc. trades at $149.91 (market cap $196.35B). The key difference: Shopify Inc. is far larger — about 74.4× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Shopify Inc. nearer its low. Which is the better fit depends on your goals.
| AMLX | SHOP | |
|---|---|---|
Market Cap | $2.64B | $196.35B |
Sector | Health | Technology |
52-Week High | $24.19 | $179.01 |
52-Week Low | $7.82 | $95.40 |
Enterprise Value | $2.39B | $191.59B |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Shopify (SHOP) trades at $155.18, up 2.38% today, following strong Q2 2026 earnings beats. The stock exhibits a bullish technical trend with support at $151 and resistance at $158. Revenue growth remains robust, with 2025 revenue reaching $11.56B, though valuation multiples like a P/E of 103.11 are elevated. Positive analyst sentiment is driven by AI commerce integration and expanding gross merchandise volume.
Outlook is positive given earnings momentum and AI-driven growth, but high valuation and competitive e-commerce pressures pose risks. The consensus price target of $166.39 suggests modest upside, supported by 65.62% of analysts rating it Buy. Investors should weigh growth prospects against premium pricing.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →